Nasdaq
$7.85▲ 0.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $615.8MShares out 78.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 6d agoPre-market26.10.19 21:008-KKey event#●●●#●●●
CorMedix Inc.Bullish
CorMedix announced that the FDA has accepted for Priority Review its supplemental New Drug Application (sNDA) for REZZAYO for the prophylaxis of invasive fungal diseases. The FDA has set a PDUFA target action date in Q1 2027, and the company is targeting a promotional launch in the second half of 2027 upon potential approval.…more
$7.85+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.19Closed26.09.19 10:364Ownership
CorMedix Inc.
Insider Janet Dillione of CorMedix Inc. reported a change in beneficial ownership of securities on September 18, 2026. This filing serves as a standard Form 4 report regarding insider equity transactions.…more
$7.85+0.06%vs prev closeView filingShare - 9.2Overnight26.09.02 09:204Ownership
CorMedix Inc.
CorMedix Inc. insider Susan Blum reported a change in beneficial ownership of company securities effective August 29, 2026. This filing, submitted via SEC Form 4, officially discloses the executive's transaction activity.…more
$7.85+0.06%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 20:30#●●●#●●●#●●●
CorMedix Receives FDA Priority Review for Rezzayo sNDA
CorMedix announced that the FDA has accepted its supplemental New Drug Application for Rezzayo for the prophylaxis of invasive fungal diseases under Priority Review. A final decision is expected in the first quarter of 2027, with potential commercial launch targeted for the second half of the year.…more
$7.85+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15Pre-market26.10.15 20:33
●●●●●●●● ●●●●● ●●●●●●
Actinium Pharmaceuticals has appointed Dr. Matt David, a veteran with over two decades of experience in biopharma and investment banking, as its new CFO. Dr. David brings extensive expertise in FDA approvals and commercialization from his previous leadership roles.…more
$7.85+0.06%vs prev closeShareBenzinga - 9.1Pre-market26.09.01 21:30
●●●●●●●● ●●●●● ●●●●●●
CorMedix announced that its senior management will participate in a fireside chat and investor meetings at the upcoming Wells Fargo Healthcare Conference. This event is a standard investor relations activity and does not provide immediate material impact on the stock price.…more
$7.85+0.06%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report